Ocular Therapeutix, Inc.

OCUL

CIK 0001393434 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$13M
↓-22.4% -$4Mvs FY2024 (Q4)
Gross Profit
$12M
↓-26.5% -$4Mvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Poor
17/100
  • Profitability
    0ROIC -44.0% (10% = solid, 20%+ = moat)
  • Liquidity
    100Current Ratio 15.39 (above 1.5 = solid)
  • Leverage
    0Insufficient data
  • Efficiency
    0Asset Turnover 0.08x (1.0+ = capital-efficient)
  • Growth
    0Revenue YoY -22.4% (10% = solid, 25%+ = elite)
  • Margin Trend
    0Op Margin -472.3% · trend -265.0pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$12M
investment in PP&E
Stock-based comp (TTM)
$43M
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$808M
everything owned
Total liabilities
$154M
everything owed
Stockholders' equity
$654M
shareholder claim
Net debt
$-719M
Net cash position ($719M)

Recent performance · 53 quarters

Revenue↓-22.4% -$4M
$13M
Net Income↓-90.2% -$33M
$-69M
Free Cash Flow↓-1305.4% -$3M
$-3M
Operating Margin↓-174.1pts
-472.3%

Drill down